Pediatric Drugs

, Volume 11, Issue 2, pp 101–113

The Role of Inhaled Corticosteroids in the Management of Cystic Fibrosis

  • Kristie R. Ross
  • James F. Chmiel
  • Michael W. Konstan
Review Article


The lung disease of cystic fibrosis (CF) is characterized by a vicious cycle of airway obstruction, chronic bacterial infection, and vigorous inflammation, which ultimately results in bronchiectasis. Recognition that excessive and persistent inflammation is a key factor in lung destruction has prompted investigation into anti-inflammatory therapies. Although effective, the use of systemic corticosteroids has been limited by the unacceptable adverse effect profile. Inhaled corticosteroids (ICS) are a widely prescribed anti-inflammatory agent in CF, likely as a result of clinicians’ familiarity with these agents and their excellent safety profile at low doses in asthmatic patients. However, while multiple studies are limited by small sample size and short duration, they consistently failed to demonstrate statistically or clinically significant benefits of ICS use in CF. This review provides an overview of the inflammatory response in CF, the mechanisms of action of corticosteroids, the safety of ICS, and the literature relevant to the use of ICS in CF.


  1. 1.
    Davis P, Drumm ML, Konstan MW. Cystic fibrosis: state of the art. Am J Respir Crit Care Med 1996; 154(5): 1229–56PubMedGoogle Scholar
  2. 2.
    Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997; 24(2): 137–42PubMedCrossRefGoogle Scholar
  3. 3.
    Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999; 115(4): 1053–8PubMedCrossRefGoogle Scholar
  4. 4.
    Konstan MW, Butler SM, Schidlow DV, et al. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Pediatr Pulmonol 1999; 28(4): 248–54PubMedCrossRefGoogle Scholar
  5. 5.
    Konstan MW, Davis PB. Pharmacological approach for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev 2002; 54: 1409–23PubMedCrossRefGoogle Scholar
  6. 6.
    Chmiel JF, Davis PB. Inflammatory responses in the cystic fibrosis lung. In: Kirk KL, Dawson DC, editors. The CFTR chloride channel. Georgetown (TX): Landes Biosci 2003; 10: 160–80Google Scholar
  7. 7.
    Chmiel JF, Konstan MW, Berger M. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23(1): 5–27PubMedCrossRefGoogle Scholar
  8. 8.
    Muhlebach MS, Stewart PW, Leigh MW, et al. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999; 160(1): 186–91PubMedGoogle Scholar
  9. 9.
    Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs [published erratum appears in Am J Respir Crit Care Med 1996 Oct; 154 (4 Pt 1): 1217]. Am J Respir Crit Care Med 1995; 152(6): 2111–8PubMedGoogle Scholar
  10. 10.
    Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151(4): 1075–82PubMedGoogle Scholar
  11. 11.
    Kirchner KK, Wagener JS, Khan TZ, et al. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996; 154(5): 1426–9PubMedGoogle Scholar
  12. 12.
    Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation [published erratum appears in Am J Respir Crit Care Med 1995 Jan; 151 (1): 260]. Am J Respir Crit Care Med 1994; 150(2): 448–54PubMedGoogle Scholar
  13. 13.
    McMorran BJ, Ouvry Patat SA, Carlin JB, et al. Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients. Clin Chem 2007; 53(10): 1782–91PubMedCrossRefGoogle Scholar
  14. 14.
    Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156(4): 1197–204PubMedGoogle Scholar
  15. 15.
    Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995; 310(6994): 1571–2PubMedCrossRefGoogle Scholar
  16. 16.
    Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150(1): 207–13PubMedGoogle Scholar
  17. 17.
    Noah TL, Black HR, Cheng P-W, et al. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997; 175(3): 638–47PubMedCrossRefGoogle Scholar
  18. 18.
    Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102(6): 1200–7PubMedCrossRefGoogle Scholar
  19. 19.
    Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 1996; 75(4): 319–22PubMedCrossRefGoogle Scholar
  20. 20.
    Bonfield TL, Konstan MW, Burfeind P, et al. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995; 13(3): 257–61PubMedGoogle Scholar
  21. 21.
    Elphick HE, Demoncheaux EAG, Ritson S, et al. Exhaled nitric oxide is reduced in infants with cystic fibrosis. Thorax 2001; 56(2): 151–2PubMedCrossRefGoogle Scholar
  22. 22.
    Ho LP, Innes JA, Greening AP. Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J 1998; 12(6): 1290–4PubMedCrossRefGoogle Scholar
  23. 23.
    Moeller A, Horak Jr F, Lane C, et al. Inducible NO synthase expression is low in airway epithelium from young children with cystic fibrosis. Thorax 2006; 61(6): 514–20PubMedCrossRefGoogle Scholar
  24. 24.
    Thomas SR, Kharitonov SA, Scott SF, et al. Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. Chest 2000; 117(4): 1085–9PubMedCrossRefGoogle Scholar
  25. 25.
    Ollero M, Junaidi O, Zaman MM, et al. Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol 2004; 200(2): 235–44PubMedCrossRefGoogle Scholar
  26. 26.
    Green S. PPAR: a mediator of peroxisome proliferator action. Mutat Res 1995; 333: 101–9PubMedCrossRefGoogle Scholar
  27. 27.
    Vanden Berghe W, Vermeulen L, Delerive P, et al. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol 2003; 544: 181–96CrossRefGoogle Scholar
  28. 28.
    Davis PB, Gupta S, Eastman J, et al. Inhibition of proinflammatory cytokine production by PPAR gamma agonists in airway epithelial cells. Pediatr Pulmonol 2003; 36Suppl. 25: 268–9Google Scholar
  29. 29.
    Auerbach H, Williams M, Kirkpatrick J, et al. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2(8547): 686–8PubMedCrossRefGoogle Scholar
  30. 30.
    Eigen H, Rosenstein B, FitzSimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis: Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995; 126(4): 515–23PubMedCrossRefGoogle Scholar
  31. 31.
    Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332(13): 848–54PubMedCrossRefGoogle Scholar
  32. 32.
    Konstan MW, Schluchter MD, Xue W, et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176(11): 1084–9PubMedCrossRefGoogle Scholar
  33. 33.
    Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian Safety and Effectiveness Trial. J Pediatrics 2007; 151(3): 249–54CrossRefGoogle Scholar
  34. 34.
    Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176(10): 957–69PubMedCrossRefGoogle Scholar
  35. 35.
    Lands L, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2007; (4): CD001505Google Scholar
  36. 36.
    Cystic Fibrosis Foundation Patient Registry 2006 Annual Data Report to the Center Directors. Bethesda (MD): Cystic Fibrosis Foundation, 2007Google Scholar
  37. 37.
    Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007; 28(2): 331–46PubMedCrossRefGoogle Scholar
  38. 38.
    Wheeler W, Williams M, Matthews WJ, et al. Progression of cystic fibrosis disease as a function of serum immunoglobulin G levels: a 5 year longitudal study. J Pediatr 1984; 104(5): 695–9PubMedCrossRefGoogle Scholar
  39. 39.
    Donati M, Haver K, Gerson W. Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatr Pulmonol 1990; 5: A322Google Scholar
  40. 40.
    Lai H-C, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342(12): 851–9PubMedCrossRefGoogle Scholar
  41. 41.
    Bhudhikanok GSB, Lim JB, Marcus RM, et al. Correlates of osteopenia in patients with cystic fibrosis. Pediatrics 1996; 97(1): 103–11PubMedGoogle Scholar
  42. 42.
    Conway SP, Morton AM, Oldroyd B, et al. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax 2000; 55(9): 798–804PubMedCrossRefGoogle Scholar
  43. 43.
    Flohr F, Lutz A, App EM, et al. Bone mineral density and quantitative ultrasound in adults with cystic fibrosis. Eur J Endocrinol 2002; 146(4): 531–6PubMedCrossRefGoogle Scholar
  44. 44.
    Fok J, Brown NE, Zuberbuhler P, et al. Low bone mineral density in cystic fibrosis patients. Can J Diet Pract Res 2002; 63(4): 192–7PubMedCrossRefGoogle Scholar
  45. 45.
    Barry SC, Gallagher CG. Corticosteroids and skeletal muscle function in cystic fibrosis. J Appl Physiol 2003; 95(4): 1379–84PubMedGoogle Scholar
  46. 46.
    Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 2000; (2): CD000407Google Scholar
  47. 47.
    Greally P, Hussain M, Vergani D, et al. Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 1994; 71(1): 35–9PubMedCrossRefGoogle Scholar
  48. 48.
    Dovey M, Aitken ML, Emerson J, et al. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007; 132(4): 1212–8PubMedCrossRefGoogle Scholar
  49. 49.
    Schiotz P, Jorgensen M, Flensborg E, et al. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: a longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr Scand 1983; 72(2): 283–7PubMedCrossRefGoogle Scholar
  50. 50.
    Van Haren EHJ, Lammers JWJ, Festen J, et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995; 89(3): 209–14PubMedCrossRefGoogle Scholar
  51. 51.
    Nikolaizik WH, Schoni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996; 128(2): 271–4PubMedCrossRefGoogle Scholar
  52. 52.
    Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997; 77(2): 124–30PubMedCrossRefGoogle Scholar
  53. 53.
    Bisgaard H, Pedersen SS, Nielsen KG, et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 156(4): 1190–6PubMedGoogle Scholar
  54. 54.
    Dauletbaev N, Viel K, Behr J, et al. Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis patients. Eur Respir J 1999; 14(5): 1150–5PubMedCrossRefGoogle Scholar
  55. 55.
    Wojtczak HA, Kerby GS, Wagener JS, et al. Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2001; 32(4): 293–302PubMedCrossRefGoogle Scholar
  56. 56.
    Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173(12): 1356–62PubMedCrossRefGoogle Scholar
  57. 57.
    De Boeck K, De Baets F, Malfroot A, et al. Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients? Eur J Pediatr 2007; 166(1): 23–8PubMedCrossRefGoogle Scholar
  58. 58.
    Ren CL, Pasta DJ, Rasouliyan L, et al. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 2008; 153(6): 746–51PubMedCrossRefGoogle Scholar
  59. 59.
    Balfour-Lynn I, Walters S, Dezateux C. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2000; 1: CD001915Google Scholar
  60. 60.
    Brown H, Storey G, George W. Beclomethasone diproprionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1972; 1(5800): 585–90PubMedCrossRefGoogle Scholar
  61. 61.
    Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1 beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20(18): 6891–903PubMedCrossRefGoogle Scholar
  62. 62.
    Auphan N, DiDonato J, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286–90PubMedCrossRefGoogle Scholar
  63. 63.
    Mittelstadt PR, Ashwell JD. Inhibition of AP-1 by the glucocorticoid-inducible protein gilz. J Biol Chem 2001; 276(31): 29603–10PubMedCrossRefGoogle Scholar
  64. 64.
    Eddleston J, Herschbach J, Wagelie-Steffen AL, et al. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. J Allergy Clin Immunol 2007; 119(1): 115–22PubMedCrossRefGoogle Scholar
  65. 65.
    Hart L, Lim SAM, Adcock IAN, et al. Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappa B in asthma. Am J Respir Crit Care Med 2000; 161(1): 224–31PubMedGoogle Scholar
  66. 66.
    Wilson SJ, Wallin A, Della-Cioppa G, et al. Effects of budesonide and formoterol on NF-kappa B, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001; 164(6): 1047–52PubMedGoogle Scholar
  67. 67.
    Cazes E, Giron-Michel J, Baouz S, et al. Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation. J Immunol 2001; 167(9): 5329–37PubMedGoogle Scholar
  68. 68.
    Corvol H, Fitting C, Chadelat K, et al. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. AJP Lung Cell Mol Physiol 2003; 284(6): L997–1003Google Scholar
  69. 69.
    Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356(9229): 556–61PubMedCrossRefGoogle Scholar
  70. 70.
    Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003; 58(3): 258–60PubMedCrossRefGoogle Scholar
  71. 71.
    Harrison TW, Wisniewski A, Honour J, et al. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001; 56(3): 186–91PubMedCrossRefGoogle Scholar
  72. 72.
    Konstan MW, Butler SM, Wohl MEB, et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003; 142(6): 624–30PubMedCrossRefGoogle Scholar
  73. 73.
    Morgan WJ, Butler SM, Johnson CA, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999; 28(4): 231–41PubMedCrossRefGoogle Scholar
  74. 74.
    Parmar JS, Howell T, Kelly J, et al. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 2002; 57(8): 749–50PubMedCrossRefGoogle Scholar
  75. 75.
    Schmidt J, Davidson A, Seear M. Is the acquistion of Pseudomonas in cystic fibrosis patients increased by the use of inhaled corticosterois? Unexpected results from a double blind placebo controlled study [abstract]. Pediatr Pulmonol 1997; 124Suppl. 14: A318Google Scholar
  76. 76.
    EPR-3. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute National Asthma Education and Prevention Program; 2007 Aug 28; Bethesda (MD)Google Scholar
  77. 77.
    Akinbami L. Asthma prevalence, health care use and mortality: United States, 2003–05. Hyattsville (MD): Centers for Disease Control and Prevention, 2007Google Scholar
  78. 78.
    Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006; 5(3): 177–85PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Kristie R. Ross
    • 1
  • James F. Chmiel
    • 1
  • Michael W. Konstan
    • 1
  1. 1.Department of Pediatrics, Division of PulmonologyCase Western Reserve University School of Medicine, Rainbow Babies and Children’s HospitalClevelandUSA
  2. 2.Pediatric PulmonologyRainbow Babies and Children’s HospitalClevelandUSA

Personalised recommendations